Navigation Links
Cytel Announces Compass® - The Only Professional Adaptive Trial Software Package for Bayesian or Frequentist Dose-Finding Studies
Date:8/4/2010

(s_account);s.linkTrackVars='prop5,eVar3,prop15';s.prop5='External Link';s.eVar3=s.prop5;s.prop15='99928384';s.tl(this,'o','ExternalLink');" target='_blank' href="http://www.cytel.com/pdfs/Quinlan_DIA_06.24.08_adaptive_dose_ranging.ppt.pdf">adaptive methods often substantially improve on traditional designs at this crucial best dose determination stage.

Wider use of adaptive trials at this stage was previously inhibited by the lack of validated commercial software. Sponsor statisticians and their regulatory counterparts could only attempt to write their own statistical design code.

The advent of Compass® provides study planners with a workflow for modern dose identification study construction using accepted adaptive methods.  The built-in high-speed simulation engine quantifies design option decision-making, while visualizations of the trial characteristics improve understanding amongst both development teams and regulators, too.

A demonstration is replay-able at: http://www.cytel.com/News/Webinars.aspx

Of the release milestone, Compass® Product Manager, Yannis Jemiai, Ph.D., said: "We're very proud of our collective work to place modern, industrial strength adaptive design tools in the hands of the drug developers engaged in dose-finding clinical research. Compass® users will more easily choose the best options and conduct successful adaptive trials. Our trial simulations implementation is based on techniques proven to help sponsors to make knowledgeable decisions time and time again."  

Ab
'/>"/>

SOURCE Cytel Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Judith Quinlan Joins Cytel as Vice President, Adaptive Trials
2. Cytels Clinical Innovation Experts Cyrus Mehta and Judith Quinlan Reveal Latest Adaptive Trial Successes at 44th Annual DIA Meeting
3. Cytel Signs Cooperative Research And Development Agreement With FDA Center for Devices and Radiological Health (CDRH)
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... March 27, 2015 The International Myeloma Foundation ... patients while working toward prevention and a cure – ... introducing a federal resolution (H. Res. 174) that supports ... "National Multiple Myeloma Awareness Month." Currently there ... and more than 110,000 new cases are diagnosed yearly, ...
(Date:3/27/2015)... , March 27, 2015  RXi ... privately-held MirImmune LLC, today announced that they ... to RXi,s novel and proprietary sd-rxRNA® technology ... immunotherapies. The collaboration has the potential to ... friendly cancer treatments that could be a ...
(Date:3/27/2015)... , March 27, 2015 ... 2015" therapeutic market research report of 52 pages ... online business intelligence library. The report ... on the therapeutic development for Visceral Pain, complete ... by drug target, mechanism of action (MoA), route ...
Breaking Medicine Technology:The International Myeloma Foundation (IMF) Secures the Introduction of a Federal Resolution Recognizing March 2015 as "National Multiple Myeloma Awareness Month" 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5Visceral Pain Pipeline Review H1 2015 Market Research Report 2Visceral Pain Pipeline Review H1 2015 Market Research Report 3Visceral Pain Pipeline Review H1 2015 Market Research Report 4
... SAN DIEGO, Dec. 10, 2010 Arena Pharmaceuticals, Inc. ... of dosing in a Phase 1 clinical trial of ... that targets the prostacyclin receptor for the treatment of ... bioavailable prostacyclin receptor agonist could improve the standard of ...
... Dec. 9, 2010 United Seating & Mobility (USM) ... is excited to announce today that it has finalized a ... Business located in Little Rock, Arkansas. Alliance Homecare ... services including oxygen, DME and sleep therapy in the Little ...
Cached Medicine Technology:Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD811 for Pulmonary Arterial Hypertension 2Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD811 for Pulmonary Arterial Hypertension 3Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD811 for Pulmonary Arterial Hypertension 4United Seating & Mobility Reaches Agreement With Alliance Homecare Equipment to Acquire its Complex Mobility Business 2
(Date:3/27/2015)... Mirada, CA (PRWEB) March 27, 2015 ... physician, Stanley G. Katz, M.D., is now treating knee ... California, including Anaheim , Long Beach, and La ... treatment of acute knee and hip joint disorders as ... Stanley Katz is passionate in returning his patients back ...
(Date:3/27/2015)... San Jose, CA (PRWEB) March 27, 2015 ... last week’s 2015 GPU technology conference (GTC) , the ... to fight cancer and push the human lifespan well beyond ... Baltimore MD informatics company , is one of 12 ... , While other startups in the GTC Emerging ...
(Date:3/27/2015)... 2015 On March 19, 2015, ... Detroit Lions wide receiver Herman Moore, hosted “Fighting ... on substance abuse, treatment options and the recent ... were pastors, ministers and bishops from local churches ... guests. , “Our ‘Fighting Addiction Together’ luncheon was ...
(Date:3/27/2015)... FL and London, UK (PRWEB) March 27, 2015 ... announced today that it has appointed Sean Fitzgerald, a ... role of Chief Operating Officer and Interim Chief Financial ... President of leading education technology innovator, EverFi, backed by ... Schmidt, and Twitter founder Evan Williams. Prior to EverFi, ...
(Date:3/27/2015)... WA (PRWEB) March 27, 2015 When ... can be hard to know where to begin. The ... experienced Seattle trucking accident attorney, offers accident victims a ... and legal assistance to ensure their personal injury claim ... begins by describing the first actions that should be ...
Breaking Medicine News(10 mins):Health News:Fellowship-Trained and Board-Certified Orthopedic Surgeon is Now Treating Knee and Hip Joint Disorders in Anaheim, California 2Health News:Fellowship-Trained and Board-Certified Orthopedic Surgeon is Now Treating Knee and Hip Joint Disorders in Anaheim, California 3Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 2Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 3Health News:LiveToBeSober.org Hosts Conference on Substance Abuse Treatment and Recovery at Ford Field 2Health News:GenSight Appoints Former Technology Executive as Chief Operating Officer 2Health News:Dax Jones Updated eBook on Trucking Accidents Offers Helpful Information to Crash Victims 2
... , TUESDAY, Nov. 16 (HealthDay News) -- Men who ... disease, new research suggests. The notion is based on ... a thickening of the men,s neck,s carotid artery wall. Such ... for heart disease. What,s more, the link between sleep ...
... TUESDAY, Nov. 16 (HealthDay News) -- A rare, but ... hyperemesis gravidarum, may be hereditary, researchers say. Each ... are hospitalized due to hyperemesis gravidarum (HG), marked by ... cause weight loss, dehydration and psychological trauma. The condition, ...
... , TUESDAY, Nov. 16 (HealthDay News) -- Bouts ... behavior over time, including their propensity for more heavy drinking, ... 500 boys in Pittsburgh who were assessed each year from ... four to five years later. When they were teens, ...
... Three-year-old Denver resident Brianna,s favorite color was yellow and her ... At 18 months she strapped on her first pair of ... loved playing with her brother and noticed everything. ... from a cardiac arrhythmia known as Long QT Syndrome. Brianna,s ...
... N.C. The National Institutes of Health (NIH), National ... Duke University Medical Center up to $52.8 million over ... and oversight of external quality assurance programs that monitor ... around the world. The project, External Quality ...
... Nov. 16 (HealthDay News) -- Hospital care-related problems contribute ... month, according to a new federal government study. ... including infections, bed sores and excessive bleeding from blood-thinning ... patients discharged from hospitals in October 2008, USA ...
Cached Medicine News:Health News:Shorter Sleep in Men Ups Risk of Heart Disease: Study 2Health News:Rare, Severe Form of Morning Sickness Appears to Be Genetic 2Health News:For Teen Boys, Heavy Drinking & Impulsivity May Be Vicious Circle 2Health News:University of Colorado in pilot project to map defibrillators 2Health News:Duke to lead oversight of HIV laboratories worldwide 2Health News:Duke to lead oversight of HIV laboratories worldwide 3Health News:Hospital Care Deadly for Some, U.S. Study Finds 2
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,408-9) or contact custom...
This adjustable-volume digital micropipet is used to accurately measure and transfer small solution volumes in the 0.5-10 microliter range....
Pipetman P is a fully adjustable, air-displacement pipette with the selected volume shown on a digital indicator (volumeter). Eight models cover the full range of volumes from 0.2 L to 10 mL....
... from Thermo Labsystems was designed specifically to ... features such as the new fast dial ... microvolumes help to define this as a ... new interchangeable handle plate offers a custom ...
Medicine Products: